[Asia Economy Reporter Jang Hyowon] GTreeBNT's largest shareholder, GTree Holdings, announced on the 23rd that the confirmation of new investors for additional share acquisition is nearing completion.
Accordingly, the previously postponed payment for the 12th series convertible bonds is expected to be finalized.
A representative of GTree Holdings stated, "We plan to finalize the payment of the convertible bonds by completing the investor confirmation," adding, "As a result, collateral was provided for GTreeBNT's shares disclosed on the 22nd, and we will resolve the collateral and acquire shares through additional investment."
Following the recent completion of Phase 3 clinical trials for dry eye syndrome with the U.S. Food and Drug Administration (FDA), GTreeBNT plans to focus its capabilities on FDA product approval applications and licensing out.
Additionally, by actively managing its pipeline to build future strategies, the company plans to recruit new talents in various fields to facilitate smooth information exchange with shareholders and institutional investors, which had been relatively insufficient.
Meanwhile, GTreeBNT has convened an extraordinary general meeting of shareholders scheduled for July 26.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
